Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Inflectra Market Size, Value And Growth Trends Through 2030
The expansion observed during the historical timeframe was fueled by the elevated expenses associated with original TNF inhibitors, along with regulatory endorsements for biosimilars, the increasing prevalence of autoimmune conditions, the integration of these therapies into hospital formularies, and cost-control measures implemented by payers.
Several factors are driving the forecast period’s growth: favorable regulations regarding biosimilars, broader patient access to biologic therapies, a rise in inflammatory disease cases, price competition, and growing familiarity among physicians. Concurrently, key trends shaping this period involve the increasing uptake of biosimilars, a shift from original biologics driven by cost considerations, an expansion in autoimmune disease treatment options, heightened physician trust in the safety profile of biosimilars, and procurement processes led by hospitals for biosimilars.
Download A Free Sample Report For Comprehensive Market Insights:
Inflectra Market Expansion Supported By Key Demand Factors
The expected market expansion for inflectra is being driven forward by the rising occurrence of autoimmune conditions. These disorders arise when the immune system mistakenly targets healthy cells, resulting in inflammation and harm to various tissues and organs. Their growing incidence can be traced to shifts in dietary habits, increased exposure to environmental pollutants, evolving lifestyle patterns, and the effects of climate change. Autoimmune diseases influence the demand for inflectra by creating a greater need for effective therapeutic solutions, as more patients seek treatments like inflectra that play a key role in managing conditions such as rheumatoid arthritis and Crohn’s disease through the inhibition of tumor necrosis factor-alpha to lower inflammation. As an example, data from September 2023 provided by the IBD Clinical and Research Centre, a Canadian organization committed to enhancing the lives of those affected by Crohn’s disease and ulcerative colitis, shows that over 320,000 Canadians were living with inflammatory bowel disease that year, reflecting a prevalence rate of 825 per 100,000 individuals. With this prevalence climbing by 2.44 percent each year, projections indicate that by 2035, 1.1 percent of Canada’s population—amounting to 470,000 people—will be diagnosed with IBD. Consequently, the escalating frequency of autoimmune diseases is fueling the expansion of the inflectra market.
A surge in clinical trial activity is anticipated to drive the growth trajectory of the inflectra market going forward. Clinical trials are structured research efforts involving human volunteers, designed to assess the effects of novel medical interventions like drugs, devices, or behavioral therapies on health outcomes, and they play a vital role in confirming both the safety and effectiveness of these interventions prior to their approval for widespread medical application. This uptick in clinical studies can be explained by the escalating demand for groundbreaking treatments and therapies, spurred by progress in medical science, the necessity for inclusive participant representation across diverse groups, and the pressing need to tackle unmet health requirements among various populations. The growing volume of clinical trials is influencing inflectra by producing comprehensive evidence regarding its efficacy and safety profile, which in turn bolsters its competitive standing in the market and increases its appeal as a therapy for autoimmune disorders. By way of illustration, a National Library of Medicine report from April 2025, originating from a U.S. governmental body, indicates that as of March 2025, ClinicalTrials.gov had catalogued 404,637 interventional studies, with an additional 27,751 new trials initiated during 2023. Therefore, the mounting number of clinical trials is propelling the advancement of the inflectra market.
Inflectra Market Segment Outlook: Which Categories Are Expanding The Fastest?
The inflectra market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Application: Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, Other Indications
3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies
Inflectra Market Growth Trends Influencing Competitive Dynamics
A significant shift in the inflectra market involves the creation of advanced therapies, particularly subcutaneous infliximab biosimilars, which aim to offer a practical and effective option for maintenance care among patients with inflammatory bowel disease through an injectable format. This subcutaneous version of infliximab serves as a user-friendly alternative for drug delivery in autoimmune conditions. As an example, in October 2023, Celltrion USA, an American branch of the biopharmaceutical firm Celltrion, secured FDA approval for ZYMFENTRA (infliximab-dyyb)—the initial subcutaneous infliximab formulation intended for managing moderately to severely active Crohn’s disease and ulcerative colitis in adults as a maintenance treatment. This new injectable preparation maintains steady concentrations of infliximab in the bloodstream, thereby offering greater convenience and flexibility for both patients and medical providers. This approval holds considerable importance because it alleviates the ongoing challenges associated with managing inflammatory bowel disorders and empowers patients with more autonomy over their treatment plans.
Inflectra Market Key Companies And Competitive Benchmarking
Major companies operating in the inflectra market are Celltrion Inc
Access The Complete Inflectra Market Report:
Inflectra Market Largest Region By Revenue And Market Share
Europe was the largest region in the inflectra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflectra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model